The use of in vitro pharmacodynamic models of infection to optimize fluoroquinolone dosing regimens

Journal of Antimicrobial Chemotherapy

Volumn 46, Issue 2, 2000, Pages 163-170

  MacGowan, A ^a   Rogers, C ^a   Bowker, K ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINAFLOXACIN; ENOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MODEL; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; REVIEW;

EID: 0033887402     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/46.2.163     Document Type: Review

References (49)

1. Comparative study of the activity of grepafloxacin and ciprofloxacin in an in vitro model with S. pneumoniae, H. influenzae and M. catarrhalis
2. Pharmacodynamics of moxifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model
3. Moxifloxacin activity against S. pneumoniae in an in vitro dynamic model
4. Pharmacodynamics of levofloxacin and ofloxacin against Streptococcus pneumoniae
5. Pharmacodynamics of fluoroquinolones
6. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection
7. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae
8. Activity of moxifloxacin administered once a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection
9. The antibacterial effects of ciprofloxacin and trovafloxacin against Streptococcus pneumoniae in an in vitro dynamic model
10. Comparative bactericidal kinetics of gatifloxacin (AM 1155) at various dosages in a pharmacodynamic model
11. Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection
12. Bactericidal activity of moxifloxacin against Staphylococcus aureus and Group A streptococci explored using a pharmacodynamic model of infection
13. In vitro models for prediction of antimicrobial activity: A pharmacokinetic and pharmacodynamic perspective
14. Questioning dosing regimens of ciprofloxacin
15. MIC-based interspecies prediction of the antimicrobial effects of ciprofloxacin on bacteria of different susceptibilities in an in vitro dynamic model
16. Pharmacodynamics of levofloxacin, ofloxacin and ciprofloxacin alone and in combination with rifampicin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model
17. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance
18. Investigation of AUC/MIC ratio as a generic predictor of fluoroquinolone activity against Staphylococcus aureus using trovafloxacin, clinafloxacin, ciprofloxacin, sparfloxacin, levofloxacin and an in vitro model
19. In vitro evaluation of pharmacodynamic outcome parameters for three fluoroquinolones against Streptococcus pneumoniae
20. Pharmacodynamic outcome parameters as predictors for fluoroquinolones in the treatment of anaerobic infection
21. Comparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi model
22. Basic pharmacodynamic concepts and models
23. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: Action of ciprofloxacin against Escherichia coli in an in vitro dynamic model
24. Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due to Pseudomonas aeruginosa
25. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model
26. Comparative antibacterial effect of ciprofloxacin dosed once or twice a day, explored using an in-vitro pharmacodynamic model of infection
27. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis
28. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials
29. Dynamics of pharmacodynamic parameters over time
30. Dose-finding investigations of intravenous ciprofloxacin in a pharmacodynamic model
31. In vivo verification of in vitro model of antibiotic treatment of device-related infection
32. The use of different pharmacodynamic parameters and descriptors of antibacterial effect in comparing once and twice a day dosing with ciprofloxacin
33. A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa
34. Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model
35. Antibacterial activity of Iomefloxacin in a pharmacokinetic in vitro model
36. Antibacterial activity of cefpodoxime proxetil in a pharmacokinetic in-vitro model
37. In vitro activity of moxifloxacin against Haemophilus influenzae and Moraxella catarrhalis investigated using a pharmacodynamic model of infection
38. A new time-kill method of assessing the relative efficacy of antimicrobial agents alone and in combination developed using a representative β-lactam, aminoglycoside and fluoroquinolone
39. Variability in antibacterial effect measures used to assess effectiveness of drug regimens in in-vitro pharmacodynamic models of infection
40. In vitro models of infection: Pharmacokinetic/pharmacodynamic correlates
41. Pharmacokinetics and pharmacodynamics of fluoroquinolones
42. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
43. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis
44. Pharmacodynamic predictors of activity for ampicillin/sulbactam and trovafloxacin versus vancomycin intermediate Staphylococcus aureus in an in vitro infection model
45. Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: New insight into a widely used concept
46. The ratio of the area-under-the-curve above MIC to the MIC is a predictor of fluoroquinolone antimicrobial effect in dynamic models
47. A new approach to in vitro comparisons of antibiotics in dynamic models: Equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities
48. In vitro characterisation of fluoroquinolone concentration/MIC, antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin oflaxacin and ciprofloxacin against multiple drug resistant isolates of Streptococcus pneumoniae
49. Pharmacodynamics of once or twice daily levofloxacin vs vancomycin ± rifampicin against Staphylococcus aureus in an in vitro model with simulated vegetations